Serological and molecular expression of Hepatitis B infection in patients with chronic Hepatitis C from Tunisia, North Africa

Virology Journal

Volumn 7, Issue , 2010, Pages

  Ben Halima, Samar ^a   Bahri, Olfa ^a   Maamouri, Nadia ^b   Cheikh, Imed ^c   Alaya, Nissaf Ben ^a   Sadraoui, Amel ^a   Azaiez, Ons ^a   Azouz, Msaddak ^b   Mami, Nabyl Ben ^d   Triki, Henda ^a  

^a PASTEUR INSTITUTE OF TUNIS   (Tunisia)

^b LA RABTA HOSPITAL   (Tunisia)

^c Departement of Gastroenterology   (Tunisia)

^d Gastroenterology Department   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; SEROLOGY; TUNISIA; VIRUS REPLICATION; ADOLESCENT; BLOOD; CLASSIFICATION; COMORBIDITY; GENETICS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; ISOLATION AND PURIFICATION; MIDDLE AGED; POLYMERASE CHAIN REACTION; VIROLOGY; VIRUS LOAD;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREVALENCE; TUNISIA; VIRAL LOAD; YOUNG ADULT;

EID: 77956529130     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-229     Document Type: Article

References (36)

1. Hepatitis B virus infection. WM Lee, N Engl J Med 1997 33 1733 1745 10.1056/NEJM199712113372406 (Pubitemid 27527771)
2. World Health Organization Hepatitis C-global prevalence (update). Wkly Epidemiol Rec 1999 74 425 427 10645164
3. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. L Benvegn G Fattovich F Noventa F Tremolada L Chemello A Cecchetto A Alberti, Cancer 1994 74 2442 2448 10.1002/1097-0142(19941101)74:9<2442::AID-CNCR2820740909>3.0.CO;2-# 7922998
4. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. M Chiaramonte T Stroffolini A Vian MA Stazi A Floreani U Lorenzoni S Lobello F Farinati R Naccarato, Cancer 1999 85 2132 2137 10.1002/(SICI)1097-0142(19990515)85:10<2132::AID-CNCR6>3.0.CO;2-H 10326690
5. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. CM Shih SJ Lo T Miyamura SY Chen YH Lee, J Virol 1993 67 5823 5832 8396658
6. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. E Sagnelli N Coppola C Scolastico P Filippini T Santantonio T Stroffolini F Piccinino, Hepatology 2000 32 1106 1110 10.1053/jhep.2000.19288 11050062
7. Hepatitis B and C virus coinfection: A novel model system reveals the absence of direct viral interference. P Bellecave J Gouttenoire M Gajer V Brass G Koutsoudakis HE Blum R Bartenschlager M Nassal D Moradpour, Hepatology 2009 50 46 55 10.1002/hep.22951 19333911
8. Suppression of hepatitis C virus by hepatitis B virus in coinfected patients at the National University Hospital of Singapore. YM Wang WC Ng SK Lo, J Gastroenterol 1999 34 481 485 10.1007/s005350050300 10452681
9. NS5A protein of HCV enhances HBV replication and resistance to interferon response. Y Pan W Wei L Kang Z Wang J Fang Y Zhu J Wu, Biochem Biophys Res Commun 2007 359 70 75 10.1016/j.bbrc.2007.05.052 17532300
10. Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection. Z Liu J Hou, Int J Med Sci 2006 3 57 62 16614744
11. Co-infection by seroligically-silent hepatitis B may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. R Fukuda N Ishimura S Hamamoto M Moritani Y Uchida S Ishihara S Akagi M Watanabe K Kinoshita, J Med Virol 2001 63 220 227 10.1002/1096-9071(200103)63:3<220::AID-JMV1004>3.0. CO;2-3 11170061
12. Prevalence of antibodies against hepatitis C virus and hepatitis B coinfection in healthy population in Bulgaria. A seroepidemiological study. MV Atanasova IA Haydouchka SP Zlatev YD Stoilova YT Iliev NG Mateva, Minerva Gastroenterol Dieto 2004 50 89 96
13. Prevalence And significance of of hepatitis C viremia in chronic active hepatitis B. J Crespo JL Lozano F de la Cruz L Rodrigo M Rodríguez G San Miguel E Artĩano F Pons- Romero, Am J Gastroenterol 1994 89 1147 1151 8053425
14. Alpha interferon therapy in chronic hepatitis due to active dual infection with hepatitis B and C viruses. RC Guptan V Thakur V Raina SK Sarin, J Gastroenterol Hepatol 1999 14 893 898 10.1046/j.1440-1746.1999.01952.x 10535471
15. Absence of hepatitis B virus DNA in patients with hepatitis C and no-A-E hepatitis in the State of Sao Paulo, Brazil. LO Souza JR Pinho FJ Carrilho LC Da Silva, Braz J Med Biol Res 2004 22 1665 1668
16. Occult hepatitis B infection and its possible impact on chronic hepatitis C virus infection. P Habibollahi S Safari NE Daryani SM Alavian, Saudi J Gastroenterol 2009 15 220 224 10.4103/1319-3767.56089 19794265
17. The epidemiology of hepatitis B in Tunisia. R Houissa Y Gharbi P Coursaget N el Goulli, Arch Inst Pasteur Tunis 1988 65 53 58 3178366
18. Seroepidemiology of hepatitis B, C and delta viruses in Tunisia. H Triki N Said A Ben Salah A Arrouji F Ben Ahmed A Bouguerra S Hmida R Dhahri K Dellagi, Trans R Soc Trop Med Hyg 1997 91 11 14 10.1016/S0035-9203(97)90374-6 9093616
19. Detection of hepatitis C virus in the general population of Tunisia. Y Gorgi S Yalaoui HL Ben Nejma MM Azzouz M Hsairi H Ben Khelifa K Ayed, Bull Soc Pathol Exot 1998 91 177 9642480
20. Contrasting patterns of hepatitis C virus infection in two regions from Tunisia. S Mejri AB Salah H Triki NB Alaya A Djebbi K Dellagi, J Med Virol 2005 76 185 193 10.1002/jmv.20342 15834884
21. Antibody to hepatitis B core antigen as a screening test for occult hepatitis B virus infection in Egyptian chronic hepatitis C patients. A El-sherif M Abou-Shady H Abou-Zeid A Elwassief A Elbahrawy Y Ueda T Chiba AM Hosney, J Gastroenterol 2009 44 359 364 10.1007/s00535-009-0020-3 19271112
22. The clinical significance of negative serological markers of hepatitis B infection in hepatitis B virus carriers with chronic hepatic disease [abstract]. N Chen C Zhu D Hu F Zeng, Zhonghua Nei Ke Za Zhi 2002 41 653 655 12485527
23. Hepatitis B infection of the liver in chronic hepatitis C without detectable hepatitis B virus DNA in serum. LF Mariscal E Rodríguez- Ĩigo J Bartolomé I Castillo N Ortiz-Movilla C Navacerrada M Pardo A Pérez-Mota J Graus V Carrẽo, J Med Virol 2004 73 177 86 10.1002/jmv.20073 15122790
24. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. R Fukuda N Ishimura M Niigaki S Hamamoto S Satoh S Tanaka Y Kushiyama Y Uchida S Ihihara S Akagi M Watanabe Y Kinoshita, J Med Virol 1999 58 201 207 10.1002/(SICI)1096-9071(199907)58:3<201::AID-JMV3>3.0.CO;2-2 10447413
25. Occult HBV infection may represent a major risk factor of non response to antiviral therapy of chronic hepatitis C. S Mrani I Chemin K Menouar O Guillaud P Pradat G Borghi, J Med Virol 2007 79 1075 1081 10.1002/jmv.20943 17596829
26. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. I Cacciola T Pollicino G Squadrito G Cerenzia ME Orlando G Raimondo, N Engl J Med 1999 341 22 26 10.1056/NEJM199907013410104 10387938
27. Genotypes of hepatitis C virus circulating in Tunisia. A Djebbi H Triki O Bahri I Cheikh A Sadraoui A Ben Ammar K Dellagi, Epidemiol Infect 2003 130 501 505 10.1017/S095026880300846X 12825736
28. Hepatitis C genotypes in patients with dual hepatitis B and C virus infection. P Pontisso M Gerotto MG Ruvoletto G Fattovich L Chemello S Tisminetzky F Baralle A Alberti, J Med Virol 1996 48 157 160 10.1002/(SICI)1096-9071(199602)48:2<157::AID-JMV7>3.0.CO;2-8 8835349 (Pubitemid 26063469)
29. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C viris core protein. G Christian Fiedler Nicola Schmidt Katja Repp Reinald H Wolfram Schaefer Stephan, J Hepatol 2002 37 855 862 10.1016/S0168-8278(02)00296-9 12445429
30. Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. SD Crockett EB Keeffe, Ann Clin Microbiol Antimicrob 2005 4 13 10.1186/1476-0711-4-13 16159399
31. Hepatitis C virus superinfection in hepatitis B virus chronic carriers: a reciprocal viral interaction and a variable clinical course. E Sagnelli N Coppola C Marrocco M Onofrio C Sagnelli G Coviello C Scolastico P Filippini, J Clin Virol 2006 35 317 320 10.1016/j.jcv.2005.10.006 16316779
32. Coinfection by hepatitis B virus and hepatitis C virus. P Pontisso M Gerotto L Benvegn L Chemello A Alberti, Antivir Ther 1998 3 137 142 10726063
33. Concurrent hepatitis B and C virus infection: Is hepatitis C virus stronger? YF Liaw, J Gastroenterol Hepatol 2001 16 597 598 10.1046/j.1440-1746. 2001.02523.x 11422609
34. Characteristics of patients with dual infection by hepatitis B and C viruses. JP Zarski B Bohn A Bastie JM Pawlotsky M Baud F Bost-Bezeaux J Tran van Nhieu JM Seigneurin C Buffet D Dhumeaux, J Hepatol 1998 28 27 33 10.1016/S0168-8278(98)80198-0 9537860
35. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. CG Schüttler N Fiedler K Schmidt R Repp WH Gerlich S Schaefer, J Hepatol 2002 37 855 862 10.1016/S0168-8278(02)00296-9 12445429
36. Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. NS Eyre RJ Phillips S Bowden E Yip B Dewar SA Locarnini MR Beard, J Hepatol 2009 51 446 457 10.1016/j.jhep.2009.04.025 19596477